Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

INTRODUCTION: Multilineage myelosuppression is an acute toxicity of cytotoxic chemotherapy, resulting in serious complications and dose modifications. Current therapies are lineage specific and administered after chemotherapy damage has occurred. Trilaciclib is a cyclin-dependent kinase 4/6 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, Lowell L., Ferrarotto, Renata, Andric, Zoran G., Beck, J. Thaddeus, Subramanian, Janakiraman, Radosavljevic, Davorin Z., Zaric, Bojan, Hanna, Wahid T., Aljumaily, Raid, Owonikoko, Taofeek K., Verhoeven, Didier, Xiao, Jie, Morris, Shannon R., Antal, Joyce M., Hussein, Maen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854399/
https://www.ncbi.nlm.nih.gov/pubmed/33123968
http://dx.doi.org/10.1007/s12325-020-01538-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854399/
https://www.ncbi.nlm.nih.gov/pubmed/33123968
http://dx.doi.org/10.1007/s12325-020-01538-0

Ejemplares similares